Pulse Biosciences (PLSE) announced that the FDA has granted approval for the company’s investigational device exemption, allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE:
- Pulse Biosciences Announces Success in Thyroid Study
- Pulse Biosciences announces first procedures in benign thyroid nodules study
- Pulse Biosciences’ Earnings Call: Clinical Gains and Financial Hurdles
- Pulse Biosciences Publishes Promising Thyroid Study Results
- Pulse Biosciences publishes benign thyroid nodules data in Journal Thyroid